SCHEMBL1763643

SCHEMBL1763643

Cc1cc(C2CCN(C(=O)c3ccc4c(c3)CCC(=O)N4)CC2)c(C(F)(F)F)cc1C(=O)NC(=N)N

nearest known ligand 0.45

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 1/20 0.45
SLC9A1 P19634 16/20 0.44
KCNH2 Q12809 2/20 0.44
NR3C1 P04150 1/20 0.41
PGR P06401 1/20 0.41
SLC6A4 P31645 1/20 0.41
PDE3B Q13370 1/20 0.41
PDE3A Q14432 1/20 0.41
CYP2C9 P11712 5/20 0.41
CYP2C19 P33261 4/20 0.40
CYP3A4 P08684 3/20 0.40
CYP2D6 P10635 2/20 0.40
SMYD3 Q9H7B4 1/20 0.40
FASN P49327 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1763674 0.91 NR3C1 (0.47) CRBNSLC9A1KCNH2NR3C1PGR
SCHEMBL12593507 0.90 CRBN (0.49) CRBNKCNH2NR3C1PGRSLC6A4
SCHEMBL1763520 0.83 SLC9A1 (0.56) SLC9A1KCNH2CYP2C9CYP2C19CYP3A4
SCHEMBL12593553 0.83 NR3C1 (0.50) CRBNKCNH2NR3C1PGRSLC6A4
SCHEMBL7991213 0.83 SLC9A1 (0.52) SLC9A1KCNH2CYP2C9CYP2C19CYP3A4
SCHEMBL1763792 0.82 SLC9A1 (0.60) SLC9A1KCNH2CYP2C9CYP2C19CYP3A4
SCHEMBL1763804 0.82 SLC9A1 (0.58) SLC9A1KCNH2CYP2C9CYP2C19CYP3A4
SCHEMBL1763688 0.80 SLC9A1 (0.46) SLC9A1KCNH2CYP2C9CYP2C19CYP3A4
SCHEMBL1763649 0.80 SLC9A1 (0.61) SLC9A1KCNH2CYP2C9CYP2C19CYP3A4
SCHEMBL1764231 0.80 SLC9A1 (0.49) SLC9A1KCNH2CYP2C9CYP2C19CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118262-A1 Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-05-19 US disclosed
US-20110118262-A1 Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-05-19 US disclosed
US-20110118262-A1 Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-05-19 US disclosed
WO-2010005783-A1 PYRROLIDINYL AND PIPERIDINYL COMPOUNDS USEFUL AS NHE-1 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118262-A1 Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors NHERF1, SLC9A1, SLC9A5 CRBN 4516/4885SLC9A1 2/4885KCNH2 242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.